A randomized, double-blind, placebo-controlled evaluation of the pharmacodynamics, pharmacokinetics, and safety of DG-051 in patients with a history of MI.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2012
At a glance
- Drugs DG 051 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 May 2012 Additional trial identifier added (DG051CV202), inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
- 02 May 2012 Actual initiation date 15 Apr 2008, trial location [Iceland] and official title added as reported by European Clinical Trials Database record.